Leerink Partnrs Issues Optimistic Outlook for TRVI Earnings

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Analysts at Leerink Partnrs raised their Q1 2025 earnings per share (EPS) estimates for shares of Trevi Therapeutics in a research report issued on Tuesday, March 18th. Leerink Partnrs analyst F. Khurshid now forecasts that the company will earn ($0.10) per share for the quarter, up from their prior estimate of ($0.13). The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.49) per share. Leerink Partnrs also issued estimates for Trevi Therapeutics’ Q2 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.45) EPS and FY2026 earnings at ($0.45) EPS.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01.

TRVI has been the topic of several other research reports. B. Riley restated a “buy” rating and set a $20.00 price objective (up previously from $11.00) on shares of Trevi Therapeutics in a report on Wednesday. Raymond James upgraded shares of Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their price target for the company from $9.00 to $29.00 in a report on Monday, March 10th. HC Wainwright restated a “buy” rating and set a $12.50 price objective on shares of Trevi Therapeutics in a report on Wednesday. Oppenheimer upped their target price on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 11th. Finally, D. Boral Capital reissued a “buy” rating and issued a $21.00 price target on shares of Trevi Therapeutics in a research note on Wednesday. Seven equities research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $17.56.

Trevi Therapeutics Price Performance

Trevi Therapeutics stock opened at $6.47 on Friday. The firm’s 50-day moving average is $4.60 and its two-hundred day moving average is $3.75. The stock has a market capitalization of $497.32 million, a P/E ratio of -14.70 and a beta of 0.90. Trevi Therapeutics has a 12-month low of $2.30 and a 12-month high of $7.39.

Insider Buying and Selling

In other Trevi Therapeutics news, insider Farrell Simon sold 81,313 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $6.75, for a total value of $548,862.75. Following the completion of the transaction, the insider now directly owns 76,900 shares in the company, valued at $519,075. This trade represents a 51.39 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 24.37% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Trevi Therapeutics

Several large investors have recently made changes to their positions in TRVI. Point72 Asset Management L.P. acquired a new position in Trevi Therapeutics during the fourth quarter worth $17,099,000. Frazier Life Sciences Management L.P. grew its position in shares of Trevi Therapeutics by 44.5% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company’s stock valued at $43,939,000 after acquiring an additional 3,283,684 shares during the period. Woodline Partners LP increased its stake in shares of Trevi Therapeutics by 429.9% during the 4th quarter. Woodline Partners LP now owns 3,212,597 shares of the company’s stock worth $13,236,000 after purchasing an additional 2,606,370 shares during the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in shares of Trevi Therapeutics in the 4th quarter valued at about $10,300,000. Finally, Acorn Capital Advisors LLC acquired a new stake in Trevi Therapeutics in the 4th quarter valued at about $8,244,000. Institutional investors and hedge funds own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.